SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a - 16 under
the
Securities Exchange Act of 1934
For
the
month of January 2007
ICON
plc
(Registrant’s
name)
0-29714
(Commission
file number)
South
County Business Park, Leopardstown, Dublin 18, Ireland.
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
|
Yes X
|
No
|
Indicate
by check mark whether the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
|
Yes
|
No X
|
Indicate
by check mark whether
the registrant is submitting the Form 6-K in paper as permitted by Regulation
S-T Rule 101(b)(7):
|
Yes
|
No X
|
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes
|
No X
|
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):82 N/A
EXHIBIT
INDEX
|
Exhibit
|
|
|
Number
|
Description
of Exhibit
|
|
99.1
|
ICON
Raises 2006 Guidance and Issues Financial Guidance for
2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
ICON plc
|
January
10, 2007
|
/s/
Peter Gray
|
|
Date
|
Peter
Gray
|
|
Chief
Executive Officer
|
|
|
|
Exhibit
99.1
ICON
raises 2006 guidance and issues financial guidance for
2007
Highlights
|
*
|
2006
Revenue guidance raised to $448 - $452
million.
|
|
*
|
2006
EPS guidance raised to $1.28 -
$1.30.
|
|
*
|
Revenue
forecast to grow 20% in 2007, compared to
2006.
|
|
*
|
2007
EPS forecast to grow 29%, compared to
2006.
|
Dublin,
Ireland, December 15, 2006 - ICON (NASDAQ: ICLR), a global provider of
outsourced development services to the pharmaceutical, biotechnology and medical
device industries, today raised its existing 2006 guidance and announced
financial guidance for 2007.
As
a
result of our strong backlog and continuing new business awards we are raising
our net revenue forecast for 2006 to a range of $448 to $452 million. Net income
per diluted share is expected to be $1.28 to $1.30 including non cash stock
compensation expense in accordance with SFAS 123R.
2007
net
revenue is expected to be in the range of $530 - $550 million, an increase
of
20% on the forecast 2006 revenue.
Net
income
per diluted share including non cash stock compensation expense in accordance
with SFAS 123R is forecast to be in the range of $1.63 - $1.71. This represents
an increase of 29% on 2006.
The
company will hold a conference call today, December 15, 2006 at 09:00 EST [14:00
Ireland & UK]. A question and answer session will follow.
The
statements made in this Press Release may contain forward-looking statements
that involve a number of risks and uncertainties. In addition to the matters
described in this Press Release, the ability to maintain large client contracts
or enter into new contracts, maintain client relationships and the ability
to
manage the opening of new offices, the integration of new business mergers
and
acquisitions, as well as other risks and uncertainties detailed from time to
time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3,
may affect the actual results achieved by ICON. ICON disclaims any intent or
obligation to update these forward-looking statements.
The
financial information presented herein has been prepared in accordance with
U.S.
GAAP.
ICON
plc
is a global provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries. The Company specializes in the
strategic development, management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical studies. ICON
teams
have successfully conducted over 1,900 development projects and over 2,300
consultancy engagements across all major therapeutic areas. ICON currently
has
over 4,100 employees, operating from 48 locations in 30 countries. Further
information is available at www.iconclinical.com.
Source:
ICON plc
Contact
:
Investor Relations 1-888-381-7923 or
Ciaran
Murray CFO + 353 -1-291-2000
Both
at
ICON.